MedTrace Logo

Persantine: Variation in Response Trial

NCT00763009 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-04-13

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.

Conditions

Interventions

DRUG

dipyridamole

0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • UConn Health

    lead OTHER

Principal Investigators

  • Michael A Azrin, MD · University of Connecticut

  • Bruce T Liang, MD · University of Connecticut

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2009-07-31
Completion
2009-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00763009 on ClinicalTrials.gov